Immunovia's Q4 Presentation: A Glimpse into the Future of Pancreatic Cancer Detection

Immunovia AB, a pioneering diagnostic company specializing in blood-based testing for early detection of pancreatic cancer, has invited analysts, investors, and media to its Q4 2024 presentation. The event, scheduled for February 25, 2025, at 8:30 am CET, will provide an update on the company's development and financial performance for the full year 2024. Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present the company's progress and answer questions during a Q&A session following the presentation.



Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm, and the company is focused on revolutionizing blood-based diagnostics to increase survival rates for patients with cancer. Its first product, IMMray™ PanCan-d, is the only blood test currently available specifically for the early detection of pancreatic cancer, with unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA, and the test is offered as a laboratory-developed test (LDT) exclusively through Immunovia, Inc.

Immunovia collaborates and engages with healthcare providers, leading experts, and patient advocacy groups globally to make its test available to all high-risk pancreatic cancer groups. The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer, with an estimated addressable market size of 1.8 million individuals per year who could benefit from the test.

In the upcoming presentation, Immunovia is expected to provide insights into its next-generation test, which is currently in development. The company has made significant progress in the discovery phase and is transitioning to leading lab platforms to lower costs and move faster. Finalizing the development and proving the value of the new test in clinical studies are key priorities for 2025, as the company aims to bring the test to the market.

Investors and analysts will be eager to learn more about Immunovia's financial performance in 2024, as well as the company's plans for growth and expansion in the coming years. The presentation will provide an opportunity to engage with the company's leadership and gain a better understanding of its strategy for driving success in the early detection market for pancreatic cancer.

In conclusion, Immunovia's Q4 presentation is an important event for investors, analysts, and healthcare providers interested in the company's progress and the future of pancreatic cancer detection. The presentation will offer valuable insights into the company's financial performance, product pipeline, and growth prospects, as well as an opportunity to engage with the company's leadership and ask questions.